Literature DB >> 23787783

A new series of heteroleptic oxidovanadium(IV) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors.

Mariana Fernández1, Javier Varela, Isabel Correia, Estefanía Birriel, Jorge Castiglioni, Virtudes Moreno, Joao Costa Pessoa, Hugo Cerecetto, Mercedes González, Dinorah Gambino.   

Abstract

Searching for prospective metal-based drugs for the treatment of Chagas disease, a new series of ten mixed-ligand oxidovanadium(IV) complexes, [V(IV)O(L-2H)(NN)], where L is a tridentate salicylaldehyde semicarbazone derivative (L1-L5) and NN is either 5-amine-1,10-phenanthroline (aminophen) or 5,6-epoxy-5,6-dihydro-1,10-phenanthroline (epoxyphen), were synthesized. The compounds were characterized in the solid state and in solution. EPR spectroscopy suggests that the NN ligands act as bidentate through both nitrogen donor atoms in an axial-equatorial mode. The stability of the complexes in solution was investigated by EPR and (51)V-nuclear magnetic resonance spectroscopies. The complexes were evaluated in vitro for their activities against Trypanosoma cruzi (T. cruzi), the parasite responsible for the disease, and their selectivity was analyzed using J-774 murine macrophages, as a mammalian model. All the complexes are more active than both the reference drug Nifurtimox and the previously reported [V(IV)O(L-2H)(NN)] complexes. In general they are more active than the corresponding free NN ligands. Complexation led to highly increased selectivities towards the parasite. In addition, the lipophilicity of the compounds was determined and correlated with the observed activity in order to perform a QSAR (quantitative structure-activity relationship) study. A clear quadratic correlation is found. This study also confirms the influence of the structure of the co-ligand on the anti-T. cruzi effect. To get insight into the mechanism of action of the compounds, the changes in biochemical pathways promoted by two of the most active and most selective complexes are studied by analyzing a few of the parasite excreted metabolites by (1)H NMR spectroscopy. The combined information suggests that the mitochondrion could be a target for these complexes. Furthermore, DNA was preliminarily evaluated as a potential target by using atomic force microscopy (AFM), which showed that the complexes display an ability to interact with this biomolecule.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23787783     DOI: 10.1039/c3dt50512j

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  8 in total

1.  New heteroleptic oxidovanadium(V) complexes: synthesis, characterization and biological evaluation as potential agents against Trypanosoma cruzi.

Authors:  Gonzalo Scalese; Ignacio Machado; Carolina Fontana; Gastón Risi; Gustavo Salinas; Leticia Pérez-Díaz; Dinorah Gambino
Journal:  J Biol Inorg Chem       Date:  2018-09-08       Impact factor: 3.358

2.  High cytotoxicity of vanadium(IV) complexes with 1,10-phenanthroline and related ligands is due to decomposition in cell culture medium.

Authors:  Maria Le; Oliver Rathje; Aviva Levina; Peter A Lay
Journal:  J Biol Inorg Chem       Date:  2017-04-03       Impact factor: 3.358

3.  Copper(II) and oxidovanadium(IV) complexes of chromone Schiff bases as potential anticancer agents.

Authors:  Patrique Nunes; Yasemin Yildizhan; Zelal Adiguzel; Fernanda Marques; João Costa Pessoa; Ceyda Acilan; Isabel Correia
Journal:  J Biol Inorg Chem       Date:  2021-11-24       Impact factor: 3.358

4.  Further aspects of Toxoplasma gondii elimination in the presence of metals.

Authors:  Laís Pessanha de Carvalho; Edésio José Tenório de Melo
Journal:  Parasitol Res       Date:  2018-02-18       Impact factor: 2.289

5.  High Throughput Approaches to Unravel the Mechanism of Action of a New Vanadium-Based Compound against Trypanosoma cruzi.

Authors:  M Florencia Mosquillo; Pablo Smircich; Analía Lima; Sergio A Gehrke; Gonzalo Scalese; Ignacio Machado; Dinorah Gambino; Beatriz Garat; Leticia Pérez-Díaz
Journal:  Bioinorg Chem Appl       Date:  2020-04-11       Impact factor: 7.778

6.  Design, synthesis and pharmacological evaluation of novel vanadium-containing complexes as antidiabetic agents.

Authors:  Elena V Fedorova; Anna V Buryakina; Alexey V Zakharov; Dmitry A Filimonov; Alexey A Lagunin; Vladimir V Poroikov
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

7.  Exploring Oxidovanadium(IV) Complexes as YopH Inhibitors: Mechanism of Action and Modeling Studies.

Authors:  Priscila G A Martins; Mattia Mori; Louise D Chiaradia-Delatorre; Angela C O Menegatti; Alessandra Mascarello; Bruno Botta; Julio Benítez; Dinorah Gambino; Hernán Terenzi
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

Review 8.  Vanadium compounds in medicine.

Authors:  Joao Costa Pessoa; Susana Etcheverry; Dinorah Gambino
Journal:  Coord Chem Rev       Date:  2014-12-09       Impact factor: 22.315

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.